Eosinophilia-myalgia syndrome

Summary

Eosinophilia-myalgia syndrome (MONDO:0004941) is a disease and 1 clinical trial. A subtype of hypereosinophilic syndrome — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	eosinophilia-myalgia syndrome
Mondo ID	MONDO:0004941
EFO	EFO:1001316
MeSH	D016603
DOID	DOID:998
ICD-11	1361333197
SNOMED CT	95416007
UMLS	C0085179
MedGen	38987
GARD	0006345
NORD	1094
Is cancer (heuristic)	no

Also known as: EMS · eosinophilia myalgia syndrome · L-tryptophan induced EMS · severe muscle pain and abnormally high eosinophils · syndrome with inflammatory and autoimmune components that affect the skin, fascia, muscle, nerve, blood vessels, lung, and heart

Disease family

This is a subtype of hypereosinophilic syndrome. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › syndromic disease › hypereosinophilic syndrome › eosinophilia-myalgia syndrome

Related subtypes (7): pulmonary eosinophilia, disseminated eosinophilic collagen disease, idiopathic hypereosinophilic syndrome, primary hypereosinophilic syndrome, secondary hypereosinophilic syndrome, hypereosinophilia of undetermined significance, episodic angioedema with eosinophilia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00001918	Not specified	COMPLETED	L-5-HTP-Related EMS